Nespo

RSS

Withdrawn

This medicine's authorisation has been withdrawn

darbepoetin alfa
MedicineHumanWithdrawn

Latvian is available via eTranslation, the European Commission's machine translation service.

Translate to Latvian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 8 June 2001 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Nespo, darbepoetin alfa, which had been approved for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients and treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy. 

The marketing authorisation holder (MAH) responsible for Nespo was Dompé Biotec S.p.A. The European Commission was notified by letter dated 10 November 2008 of the MAH’s decision to voluntarily withdraw the marketing authorisation for Nespo for commercial reasons. 

On 5 December 2008 the European Commission issued a decision to withdraw the marketing authorisation for Nespo. 

Pursuant to this decision the European Public Assessment Report for Nespo is updated to reflect that the marketing authorisation is no longer valid.

български (BG) (427.41 KB - PDF)

Skatīt

español (ES) (265.94 KB - PDF)

Skatīt

čeština (CS) (405.67 KB - PDF)

Skatīt

dansk (DA) (265.54 KB - PDF)

Skatīt

Deutsch (DE) (266.85 KB - PDF)

Skatīt

eesti (ET) (265.84 KB - PDF)

Skatīt

ελληνικά (EL) (427.54 KB - PDF)

Skatīt

français (FR) (266.83 KB - PDF)

Skatīt

italiano (IT) (268.66 KB - PDF)

Skatīt

latviešu (LV) (413.33 KB - PDF)

Skatīt

lietuvių (LT) (380.87 KB - PDF)

Skatīt

magyar (HU) (399.21 KB - PDF)

Skatīt

Malti (MT) (410.13 KB - PDF)

Skatīt

Nederlands (NL) (265.59 KB - PDF)

Skatīt

polski (PL) (414.04 KB - PDF)

Skatīt

português (PT) (268.95 KB - PDF)

Skatīt

română (RO) (374.99 KB - PDF)

Skatīt

slovenčina (SK) (401.7 KB - PDF)

Skatīt

slovenščina (SL) (392.39 KB - PDF)

Skatīt

suomi (FI) (305.78 KB - PDF)

Skatīt

svenska (SV) (265.47 KB - PDF)

Skatīt

Product information

български (BG) (7.33 MB - PDF)

Skatīt

español (ES) (3.86 MB - PDF)

Skatīt

čeština (CS) (5.01 MB - PDF)

Skatīt

dansk (DA) (3.72 MB - PDF)

Skatīt

Deutsch (DE) (3.87 MB - PDF)

Skatīt

eesti (ET) (3.39 MB - PDF)

Skatīt

ελληνικά (EL) (7.83 MB - PDF)

Skatīt

français (FR) (3.88 MB - PDF)

Skatīt

italiano (IT) (3.84 MB - PDF)

Skatīt

latviešu (LV) (5.58 MB - PDF)

Skatīt

lietuvių (LT) (4.9 MB - PDF)

Skatīt

magyar (HU) (4.37 MB - PDF)

Skatīt

Malti (MT) (4.83 MB - PDF)

Skatīt

Nederlands (NL) (3.86 MB - PDF)

Skatīt

polski (PL) (5.93 MB - PDF)

Skatīt

português (PT) (3.86 MB - PDF)

Skatīt

română (RO) (5.26 MB - PDF)

Skatīt

slovenčina (SK) (4.59 MB - PDF)

Skatīt

slovenščina (SL) (4.04 MB - PDF)

Skatīt

suomi (FI) (3.61 MB - PDF)

Skatīt

svenska (SV) (3.55 MB - PDF)

Skatīt
Latest procedure affecting product information:II/0047
28/10/2008
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (388.89 KB - PDF)

Skatīt

español (ES) (248.4 KB - PDF)

Skatīt

čeština (CS) (359.84 KB - PDF)

Skatīt

dansk (DA) (245.89 KB - PDF)

Skatīt

Deutsch (DE) (244.7 KB - PDF)

Skatīt

eesti (ET) (246.35 KB - PDF)

Skatīt

ελληνικά (EL) (369.59 KB - PDF)

Skatīt

français (FR) (248.5 KB - PDF)

Skatīt

italiano (IT) (246.05 KB - PDF)

Skatīt

latviešu (LV) (362.35 KB - PDF)

Skatīt

lietuvių (LT) (341.15 KB - PDF)

Skatīt

magyar (HU) (360.85 KB - PDF)

Skatīt

Malti (MT) (371.87 KB - PDF)

Skatīt

Nederlands (NL) (246.7 KB - PDF)

Skatīt

polski (PL) (368.01 KB - PDF)

Skatīt

português (PT) (245.61 KB - PDF)

Skatīt

română (RO) (343.92 KB - PDF)

Skatīt

slovenčina (SK) (356.54 KB - PDF)

Skatīt

slovenščina (SL) (310.69 KB - PDF)

Skatīt

suomi (FI) (242.85 KB - PDF)

Skatīt

svenska (SV) (244.24 KB - PDF)

Skatīt

Product details

Name of medicine
Nespo
Active substance
darbepoetin alfa
International non-proprietary name (INN) or common name
darbepoetin alfa
Therapeutic area (MeSH)
  • Kidney Failure, Chronic
  • Anemia
  • Cancer
Anatomical therapeutic chemical (ATC) code
B03XA02

Pharmacotherapeutic group

Antianemic preparations

Therapeutic indication

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients.
Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

Authorisation details

EMA product number
EMEA/H/C/000333
Marketing authorisation holder
Dompé Biotec S.p.A.

Via San Martino 12
I-20122 Milan
Italy

Marketing authorisation issued
08/06/2001
Withdrawal of marketing authorisation
05/12/2008
Revision
19

Assessment history

This page was last updated on

Share this page